Searched for
DARZALEX
JNJ stock price today: Why Johnson & Johnson shares dropped despite strong 2026 forecast? Here's what investors are watchingJNJ stock price today: Johnson & Johnson stock saw a dip even as the company projected robust 2026 sales and profit figures. Legal issues, ...- Glenmarkâs blood cancer drug ISB 2001 shows promising results in trialIchnos Glenmark Innovation's ISB 2001 has shown promising results in treating relapsed or refractory multiple myeloma (RRMM), demonstrating...
- Johnson & Johnson earnings beat estimates on strong cancer drug salesJohnson & Johnson's first-quarter revenue and profit exceeded Wall Street expectations, driven by strong cancer drug sales. The company rai...
- Chinaâs biotech is redrawing the global pharma map; what India can learnAmerican biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma treatment. Astr...
- Dr Reddy's unit ties up with Shanghai Henlius BiotechDr Reddy's Laboratories has partnered with Shanghai Henlius Biotech to develop and commercialize HLX15, a biosimilar to the cancer drug Dar...
- J&J Q2 Results: Pharma major beats Wall Street estimates on strong drug salesJohnson & Johnson beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer ...
- GSK blood cancer drug nearly halves risk of death in late-stage trialIn the trial of 302 patients with relapsed or difficult-to-treat multiple myeloma, 71% of those who received Blenrep in combination with th...
- J&J issues cautious 2023 forecast, shares fallThe company was "responsibly optimistic" about 2023, Chief Financial Officer Joseph Wolk said on a conference call, pointing to fierce comp...
- Johnson & Johnson plans to split into two companiesThe healthcare company will separate its consumer health business into a new publicly traded company and is aiming to complete the planned ...
- Johnson & Johnson Q1 profit, sales jump, beats Wall Street forecastThe one weak spot was a small drop in consumer health sales, which saw a surge in 2020's first quarter, when nervous consumers stocked up o...
- J&J beats profit estimates but coronavirus fuels forecast cutJohnson & Johnson is the first major U.S. drugmaker to report earnings since the coronavirus outbreak.
Load More
